These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

515 related articles for article (PubMed ID: 8861551)

  • 1. Muromonab CD3: a reappraisal of its pharmacology and use as prophylaxis of solid organ transplant rejection.
    Wilde MI; Goa KL
    Drugs; 1996 May; 51(5):865-94. PubMed ID: 8861551
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Basiliximab: a review of its use as induction therapy in renal transplantation.
    Chapman TM; Keating GM
    Drugs; 2003; 63(24):2803-35. PubMed ID: 14664658
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibody induction therapy for lung transplant recipients.
    Penninga L; Møller CH; Penninga EI; Iversen M; Gluud C; Steinbrüchel DA
    Cochrane Database Syst Rev; 2013 Nov; 2013(11):CD008927. PubMed ID: 24282128
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polyclonal and monoclonal antibodies for induction therapy in kidney transplant recipients.
    Hill P; Cross NB; Barnett AN; Palmer SC; Webster AC
    Cochrane Database Syst Rev; 2017 Jan; 1(1):CD004759. PubMed ID: 28073178
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A pharmacoeconomic comparison of antithymocyte globulin and muromonab CD3 induction therapy in renal transplant recipients.
    Brennan DC; Schnitzler MA; Baty JD; Ceriotti CS; Lowell JA; Shenoy S; Howard TK; Woodward RS
    Pharmacoeconomics; 1997 Mar; 11(3):237-45. PubMed ID: 10165313
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polyclonal and monoclonal antibodies for treating acute rejection episodes in kidney transplant recipients.
    Webster AC; Wu S; Tallapragada K; Park MY; Chapman JR; Carr SJ
    Cochrane Database Syst Rev; 2017 Jul; 7(7):CD004756. PubMed ID: 28731207
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Muromonab-CD3 and antithymocyte globulin in renal transplantation.
    Burk ML; Matuszewski KA
    Ann Pharmacother; 1997 Nov; 31(11):1370-7. PubMed ID: 9391693
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibody induction therapy in renal transplant patients receiving calcineurin-inhibitor immunosuppressive regimens: a comparative review.
    Nashan B
    BioDrugs; 2005; 19(1):39-46. PubMed ID: 15691216
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized prospective study comparing low-dose OKT3 to low-dose ATG for the treatment of acute steroid-resistant rejection episodes in kidney transplant recipients.
    Mariat C; Alamartine E; Diab N; de Filippis JP; Laurent B; Berthoux F
    Transpl Int; 1998; 11(3):231-6. PubMed ID: 9638854
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prophylactic therapy for rejection after cardiac transplantation. A comparison of rabbit antithymocyte globulin and OKT3.
    Kirklin JK; Bourge RC; White-Williams C; Naftel DC; Thomas FT; Thomas JM; Phillips MG
    J Thorac Cardiovasc Surg; 1990 Apr; 99(4):716-24. PubMed ID: 2108282
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Muromonab CD3. A review of its pharmacology and therapeutic potential.
    Todd PA; Brogden RN
    Drugs; 1989 Jun; 37(6):871-99. PubMed ID: 2503348
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antilymphocyte globulins versus OKT3 as prophylactic treatment in highly sensitized renal transplant recipients.
    Vela C; Cristol JP; Chong G; Okamba A; Lorho R; Mion C; Mourad G
    Transpl Int; 1994; 7 Suppl 1():S259-62. PubMed ID: 11271219
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Symptomatic cytomegalovirus infection in renal transplant recipients given either Minnesota antilymphoblast globulin (MALG) or OKT3 for rejection prophylaxis.
    Bailey TC; Powderly WG; Storch GA; Miller SB; Dunkel JD; Woodward RS; Spitznagel E; Hanto DW; Dunagan WC
    Am J Kidney Dis; 1993 Feb; 21(2):196-201. PubMed ID: 8381577
    [TBL] [Abstract][Full Text] [Related]  

  • 14. OKT3 escalating dose regimens provide effective therapy for renal allograft rejection.
    Woodle ES; Bruce DS; Josephson M; Cronin D; Newell KA; Millis JM; Piper JB; O'Laughlin R; Thistlethwaite JR
    Clin Transplant; 1996 Aug; 10(4):389-95. PubMed ID: 8884115
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction immunosuppression in kidney transplant recipients older than 60 years of age : safety and efficacy of ATGAM, OKT3 and Simulect.
    Heifets M; Saeed MI; Parikh MH; Sierka D; Kumar MS
    Drugs Aging; 2004; 21(11):747-56. PubMed ID: 15323580
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antilymphocyte globulin versus OKT3 induction therapy in cadaveric kidney transplantation: a prospective randomized study.
    Grino JM; Castelao AM; Serón D; Gonzalez C; Galceran JM; Gil-Vernet S; Andrés E; Mestre M; Torras J; Alsina J
    Am J Kidney Dis; 1992 Dec; 20(6):603-10. PubMed ID: 1462990
    [TBL] [Abstract][Full Text] [Related]  

  • 17. OKT3 induction and steroid-free maintenance immunosuppression for treatment of high-risk heart transplant recipients.
    Prieto M; Lake KD; Pritzker MR; Jorgensen CR; Arom KV; Love KR; Emery RW
    J Heart Lung Transplant; 1991; 10(6):901-11. PubMed ID: 1661608
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction immunosuppression for lung transplantation with OKT3.
    Wain JC; Wright CD; Ryan DP; Zorb SL; Mathisen DJ; Ginns LC
    Ann Thorac Surg; 1999 Jan; 67(1):187-93. PubMed ID: 10086547
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-CD3 monoclonal antibody induction therapy. Immunological equivalency with triple-drug therapy in heart transplantation.
    Barr ML; Sanchez JA; Seche LA; Schulman LL; Smith CR; Rose EA
    Circulation; 1990 Nov; 82(5 Suppl):IV291-4. PubMed ID: 2121387
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction immunosuppression with antilymphocyte globulin or OKT3 in cadaver kidney transplantation. Results of a single institution prospective randomized trial.
    Hanto DW; Jendrisak MD; So SK; McCullough CS; Rush TM; Michalski SM; Phelan D; Mohanakumar T
    Transplantation; 1994 Feb; 57(3):377-84. PubMed ID: 8108873
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.